Pipeline

Large need as treatment for late incidence of paracetamol poisoning is missing

The Market

Paracetamol – the most sold drug (pills) in the world

In 2012, the use of paracetamol amounted to 150 billion doses, of which the US – the largest single market – accounted for 19 billion. In Sweden, paracetamol is the active compound in well-known brands such as Alvedon, Panodil and Citodon. On several occasions, the United States Food and Drug Administration (FDA) has described paracetamol poisoning as a growing problem, and various measures such as restricted availability, lower-strength tablets and smaller packages have been proposed to reduce the risk of poisoning.

Measures have also been introduced in Sweden to limit the availability of paracetamol sold over the counter, due to the recent and dramatic rise in overdoses. In 2012, there were 1,500-2,000 hospital admissions for paracetamol poisoning in Sweden. Some patients receive liver transplants, which are not only an expensive medical procedure but also a major intervention and cause of suffering for the patient.

The problem with NAC treatment is that its efficacy gradually decreases and after 15 hours, the antidote effects have more or less disappeared. According to leading clinicians and researchers in paracetamol poisoning, as well as scientific literature, the proportion of patients arriving after eight hours is an estimated 25-30% of all cases of paracetamol poisoning – patients in need of treatment that is effective for longer than the eight-hour window.

At present, PledPharma is not aware of any compounds on the market or in clinical phase that are designed for these patients. PledPharma’s drug candidate Aladote® therefore has the potential to become the leading drug in this key area.

High costs

The cost of treating paracetamol-poisoned patients is very high because they need intensive care and, in some cases, a liver transplant is the only option for saving the patient’s life. An effective treatment for late-stage poisoning cases would have major life-saving potential and reduce the burden of healthcare costs.

Share

Facebook
Twitter
LinkedIn
RSS

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com